News for Arrowhead Pharmaceuticals, Inc. (0HI3.L)

Summary Arrowhead Pharmaceuticals Inc (ARWR) announced on May 13, 2025, that its Chief Financial Officer, Ken Myszkowski, will retire after 16 years of service.

\nArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that, effective May 13, 2025, Arrowhead's Chief Financial Officer, Ken Myszkowski, will retire a

Summary Arrowhead Pharmaceuticals Inc (ARWR) announced on April 3, 2025, that its Board of Directors has approved inducement grants for 21 new employees. These

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for my updated look at ARWR stock.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced topline results from Part 2 of a Phase 1/2 clinical study of ARO-C3, the company's investigation

Arrowhead Pharmaceuticals Inc (ARWR) has announced the expansion of its

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) marks Rare Disease Day with the expansion of the We'll Get There Soon campaign, initially launched for healthcar

Summary Arrowhead Pharmaceuticals Inc (ARWR) announced preclinical results for ARO-ALK7, an investigational RNA interference (RNAi) therapeutic targeting Activi

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company's investigational RNA interference (RNAi) therapeut

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc.

On December 31, 2024, Aquilo Capital Management, LLC (Trades, Portfolio) made a significant move by acquiring an additional 410,059 shares of Precision BioScien

On December 31, 2024, Avoro Capital Advisors LLC (Trades, Portfolio) executed a significant transaction involving Arrowhead Pharmaceuticals Inc. The firm added

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ETCompany ParticipantsChris Anzalone - President...

Guidewire stock soars on S&P 400 inclusion, Goldman Sachs Buy rating

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

Arrowhead Pharmaceuticals Inc (ARWR) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for plozasiran, an i

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for

Arrowhead Pharmaceuticals' chief sells $648,824 in stock

Arrowhead Pharmaceuticals CEO sells $219,456 in stock